Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

NCT ID: NCT03911076

Last Updated: 2024-06-17

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-05-22
• Study Completion Date: 2022-06-08

Brief Summary

• To evaluate the safety and tolerability of the dual IM pNGVL4a Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen
• To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen on Human Papillomavirus (HPV) 16 clearance by Month 6

Detailed Description

Patients with human papillomavirus type 16 (HPV16) infection and low-grade cervical dysplasia [low-grade squamous intraepithelial lesion (LSIL)/CIN1] or atypical squamous cells [atypical squamous cells of undetermined significance (ASC-US)/atypical squamous cells- cannot exclude high-grade squamous intraepithelial lesion (ASC-H)] require active surveillance for disease progression. A safe and effective immunotherapy to clear HPV16 is an unmet medical need. This study (NCT03911076) is a randomized double-blind, placebo-controlled phase II trial of PVX2 [vaccination twice with HPV16-targeting pNGVL4a-Sig/E7(detox)/HSP70 plasmid and once with the HPV16 L2E7E6 fusion protein "TA-CIN"] as immunotherapy for patients with HPV16+ ASC-US, ASC-H, or LSIL/CIN1. The primary objective of this cohort is to determine the safety and tolerability of PVX2 in three monthly immunizations. Subjects are confirmed to have HPV16 infection and LSIL/CIN1, ASC-US, or ASC-H. Adverse events are evaluated using Common Terminology Criteria for Adverse Events v5.0. HPV typing by HPV16 18/45 Aptima Assay is performed at baseline, month 6, and month 12, with simultaneous cytology analysis. Cervical biopsies and endocervical curettage are performed at baseline and month 6. In a safety run-in cohort 12 eligible patients are enrolled prior to the randomized phase.

Conditions

ASC-US; ASC-H; LSIL

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

PVX-2

Prime: 3 mg pNGVL4a-Sig/E7(detox)/HSP70 DNA Boost: 0.1 mg TA-CIN protein

Group Type: EXPERIMENTAL

PVX-2

Intervention Type: BIOLOGICAL

pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)

Placebo

Prime: PBS (Phosphate Buffered Saline) Boost: PGC (Phosphate Glycine Cysteine Buffer)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

PBS and PGC

Interventions

PVX-2

pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)

Intervention Type: BIOLOGICAL

Placebo

PBS and PGC

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Female subjects age 25-70 years with confirmation of ASC-US, ASC-H, or LSIL by liquid-based cytology

2. HIV uninfected

3. Patients whose cytologic specimen is HPV16+ by Aptima HPV 16 18/45 Genotype Assay

4. Body Mass Index ≤ 32 kg/m2

5. Hepatitis B surface antigen negative

6. Anti-hepatitis C virus antibody (anti-HCV) negative or negative HCV PCR if anti-HCV positive

7. Patients who are able and willing to comply with all study procedures and voluntarily sign an informed consent form, and with anticipated availability for the planned follow-up period of one year

8. Patients who are of childbearing potential agree to remain sexually abstinent, use methods of contraception (e.g. oral contraception, barrier methods, spermicide, intrauterine device (IUD)), or have a partner who is sterile (i.e., vasectomy) through 6 months.

9. Patients must have adequate organ function at the time of enrollment as defined by the following parameters: white blood cell count >3,000/mcL; lymphocyte number >500/mcL; absolute neutrophil count >1,000/mcL; platelets >90,000/mcL; hemoglobin >9 g/dL; total bilirubin <3 X the institutional limit of normal; aspartate aminotransferase (AST [SGOT]) / alanine aminotransferase (ALT [SGPT]) <3 X the institutional limit of normal; creatinine <2.5X the institutional limit of normal.

10. Histologic diagnosis of <CIN2 upon screening colposcopic examination with mandatory ECC, and cervical biopsy(ies) as clinically indicated.

Exclusion Criteria

1. Patients who are attempting pregnancy within 6 months, pregnant, or breastfeeding.

2. Patients with immunodeficiency, or treatment with immunosuppressive medications

3. Administration of any blood product within 3 months of enrollment.

4. Administration of any licensed vaccine within 2 weeks of enrollment (4weeks for measles vaccine)

5. Participation in a study with an investigational compound or device within 30 days of signing informed consent.

6. History of seizures (unless seizure free for 5 years)

7. Patients with positive serological test for human immunodeficiency virus (HIV).

8. Previous cancer history within the past 5 years.

9. Patients who have had chemotherapy, radiation, biological cancer therapy, or other investigational agents within 28 days prior to the first dose of study drug.

10. Patients who have had surgery within 28 days, excluding minor procedures (dental work, skin biopsy, etc).

11. Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing, or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

12. Patients who have an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis).

13. Patients with a recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia; patients who have acquired, hereditary, or congenital immunodeficiencies; patients being chronically treated with immunosuppressive drugs such as cyclosporin, adrenocorticotropic hormone (ACTH), or systemic corticosteroids

14. Previous cervical conization or LEEP procedure or previous total hysterectomy due to cervical lesions at enrollment.

• Minimum Eligible Age: 25 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Parexel

INDUSTRY

Sponsor Role: collaborator

PapiVax Biotech, Inc.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark Einstein, MD, MS

Role: PRINCIPAL_INVESTIGATOR

Professor and Chairman, Dept. of OBS&GYN, Rutgers New Jersey Medical School, Newark, NJ 07101

Locations

Health Awareness, Inc.

Port Saint Lucie, Florida, United States

University Hospital, Rutgers New Jersey Medical School

Newark, New Jersey, United States

Obstetrics & Gynecology Associates, Inc.

Fairfield, Ohio, United States

Austin Area Obstetrics, Gynecology, and Fertility

Austin, Texas, United States

Corpus Christi Women's Clinic (Elligo Health Research, Inc.)

Corpus Christi, Texas, United States

MacArthur Medical Center

Irving, Texas, United States

Countries

United States

References

Einstein MH, Roden RBS, Ferrall L, Akin M, Blomer A, Wu TC, Chang YN. Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1. Cancer Prev Res (Phila). 2023 Apr 3;16(4):219-227. doi: 10.1158/1940-6207.CAPR-22-0413.

Reference Type: RESULT

PMID: 36607735 (View on PubMed)

Related Links

https://pubmed.ncbi.nlm.nih.gov/36607735/

Study report

Other Identifiers

PVX2TACIN17368

Identifier Type: -

Identifier Source: org_study_id